Intercept Pharmaceuticals Inc to Post FY2018 Revenue of ($10.21) Per Share, Wedbush Forecasts (ICTarget Price)

Intercept Pharmaceuticals Inc to Post FY2018 Revenue of ($10.21) Per Share, Wedbush Forecasts (ICTarget Price)

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Equities research analysts at Wedbush upped their FY2018 earnings estimates for shares of Intercept Pharmaceuticals in a report issued on Tuesday, November 6th. Wedbush analyst L. Moussatos now forecasts that the biopharmaceutical company will post earnings of ($10.21) per share for the year, up from their previous estimate of ($11.09). Wedbush currently has a “Buy” rating and a $220.00 target price on the stock. Wedbush also issued estimates for Intercept Pharmaceuticals’ Q4 2018 earnings at ($2.33) EPS, Q1 2019 earnings at ($2.31) EPS, Q2 2019 earnings at ($2.14) EPS, Q3 2019 earnings at ($1.91) EPS, Q4 2019 earnings at ($1.70) EPS, FY2019 earnings at ($8.06) EPS, FY2020 earnings at ($2.75) EPS, FY2021 earnings at $7.69 EPS and FY2022 earnings at $17.77 EPS.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Wednesday, October 31st. The biopharmaceutical company reported ($2.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.65) by $0.47. The business had revenue of $47.00 million for the quarter, compared to analysts’ expectations of $48.24 million. Intercept Pharmaceuticals had a negative return on equity of 645.54% and a negative net margin of 202.93%. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.89) EPS.

Several other brokerages have also recently weighed in on ICPT. ValuEngine cut Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 2nd. BidaskClub upgraded Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 2nd. Laidlaw cut Intercept Pharmaceuticals from a “buy” rating to a “hold” rating and upped their price objective for the company from $90.00 to $95.00 in a report on Friday, August 3rd. Roth Capital assumed coverage on Intercept Pharmaceuticals in a report on Wednesday, September 12th. They issued a “buy” rating and a $192.00 price objective on the stock. Finally, Cantor Fitzgerald set a $69.00 price objective on Intercept Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, August 2nd. Nine equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $140.06.

Shares of Intercept Pharmaceuticals stock opened at $108.81 on Friday. The company has a market cap of $3.39 billion, a PE ratio of -7.57 and a beta of -1.08. Intercept Pharmaceuticals has a 1-year low of $51.05 and a 1-year high of $133.74. The company has a debt-to-equity ratio of 3.83, a quick ratio of 5.98 and a current ratio of 5.98.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ICPT. Strs Ohio purchased a new stake in Intercept Pharmaceuticals in the third quarter valued at approximately $126,000. Chicago Equity Partners LLC purchased a new stake in Intercept Pharmaceuticals in the third quarter valued at approximately $215,000. GWM Advisors LLC purchased a new stake in Intercept Pharmaceuticals in the third quarter valued at approximately $220,000. Tocqueville Asset Management L.P. purchased a new stake in Intercept Pharmaceuticals in the second quarter valued at approximately $252,000. Finally, Sheaff Brock Investment Advisors LLC purchased a new stake in Intercept Pharmaceuticals in the second quarter valued at approximately $264,000. Hedge funds and other institutional investors own 70.07% of the company’s stock.

In related news, insider David Shapiro sold 759 shares of the company’s stock in a transaction that occurred on Friday, October 5th. The stock was sold at an average price of $110.65, for a total value of $83,983.35. Following the transaction, the insider now directly owns 39,152 shares in the company, valued at $4,332,168.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 11,101 shares of company stock worth $1,177,128 over the last quarter. 4.90% of the stock is currently owned by insiders.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Read More: What is a stock buyback?

Related posts

Leave a Comment